MedTrace Logo

Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer

NCT01166737 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 408

Last updated 2022-01-25

No results posted yet for this study

Summary

It is still not clear whether a positive AGO-score just selects patients with less aggressive biologic tumor behavior who as well would have had a positive outcome by chemotherapy only, or , if it is a score selecting patients who really benefit from surgery. Nevertheless, the AGO-score was confirmed to select patients with a less than 30% risk of ending with residual tumor after surgery for recurrent disease. This could avoid including patients into the present surgical protocol who could not benefit from an operationThe goal of this third DESKTOP study is to evaluate in a prospectively randomized multicentre setting, whether maximum effort of cytoreductive surgery followed by platinum based combination chemotherapy can improve overall survival as compared to platinum based combination chemotherapy alone in AGO-score positive patients.

Conditions

Interventions

PROCEDURE

Tumor Debulking Surgery (surgery in recurrent ovarian disease)

Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection

Sponsors & Collaborators

  • ARCAGY/ GINECO GROUP

    collaborator OTHER

  • Grupo Español de Investigación en Cáncer de Ovario

    collaborator OTHER

  • Cancer Research UK

    collaborator OTHER

  • Shanghai Gynecologic Oncology Group

    collaborator OTHER_GOV

  • AGO Study Group

    lead OTHER

Principal Investigators

  • Philipp Harter, MD · AGO Study Group

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2020-01-17
Completion
2020-12-31

Countries

  • Austria
  • Belgium
  • China
  • Denmark
  • France
  • Germany
  • Italy
  • Norway
  • South Korea
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01166737 on ClinicalTrials.gov